|
|
|
 |
|
 is honored to present coverage from the 4th Friends of Israel Urological Symposium (FOIU) held in Tel Aviv, Israel. The 2018 Symposium creates an unparalleled opportunity for local and international Urologists, Oncologists, Uro-pathologists and Uro-radiologists to meet in Israel for an unforgettable scientific and social forum of high-level scientific content with lectures by Israel's world-renowned leaders, to provide you with a "taste of Israel."
|
|
|
|
|
Ureteoscopic Management of Upper Tract UC: Time to Update the Guidelines?
Scott Hubosky, MD, began his talk with the change that the current European Urology guidelines have made regarding the indication for kidney preservation treatment for low-grade upper tract urothelial carcinoma (UTUC). The change from 2015 to 2018 is that the upper limit of tumor size increased from 1 cm to 2 cm.
|
|
|
|
|
Should the Primary be Treated in Patients with Metastatic Disease? - Upper Tract Urothelial Cancer
Seth Lerner, MD discussed the topic of treating the primary tumor in patients with metastatic upper tract urothelial carcinoma (MUTUC). The outline of his talk included the unique biology of UTUC disease, the incidence and patterns of metastasis of UTUC, the efficacy of systematic chemotherapy, the outcomes of post systemic treatment, and locoregional surgical consolidation.
|
|
|
|
|
Bladder Cancer – Oncologist’s View
Raya Leibowitz-Amit, MD discussed the topic of whether we should treat the primary tumor in patients with metastatic bladder cancer. First, Dr. Leibowitz presented the potential harm in treating the primary tumor.
|
|
|
|
|
Current Experience in Immunotherapy for Metastatic Bladder Cancer
Avishay Sella, MD gave a talk about the evolution of immunotherapy in bladder cancer. The immunologic systemic therapy for urothelial cancer has significantly progressed in recent years. Currently, there are 5 FDA approved medications for use in bladder cancer.
|
|
|
|
|
Immunotherapy as an Early Treatment? What Have We Learned From Other Malignancies?
Daniel Goldstein, MD, gave a talk on the possibility of immunotherapy given as at an earlier stage. The role of immunotherapy in the adjuvant/neoadjuvant setting is still being explored and studied. The utility of immunotherapy in metastatic urologic cancers is still being analyzed.
|
|
|
|
|
Urothelial Carcinoma of the Upper Tract Following Radical Cystectomy
Seth Lerner, MD, gave an overview of urothelial carcinoma of the upper tract occurring following radical cystectomy. He began his talk mentioning a systematic review including 57 studies, demonstrating an incidence of UTUC following RC of 4-10%.
|
|
|
|
|
Current Experience in Immunotherapy for Metastatic Renal Cell Carcinoma
Axel Bex, MD gave an overview of immunotherapy in metastatic renal cell carcinoma. Immune checkpoint inhibitors have changed the RCC treatment landscape. Checkmate 025 trial which compared Nivolumab vs. Everolimus in 2nd line MRCC demonstrated an improved median overall survival for nivolumab of 25 vs. 19.6 months, p=0.002.
|
|
|
|
|
Should the Primary be Treated in Patients with Metastatic Disease? - Kidney Cancer
The current NCCN guidelines recommend performing CN for a select group of metastatic patients. However, it is important to know what the possible disadvantages of this procedure. These include morbidity/mortality associated with major surgery and disease progression during the recovery period.
|
|
|
|
|
Does Checkpoint Inhibition Work in Prostate Cancer?
Raanan Berger, MD presents an overview of the utility of immune checkpoint inhibitors in prostate cancer (PC). Immunotherapy in PC is not a new concept. The phase-3 study assessing Sipuleucel-T, demonstrated a 4 months survival benefit to this vaccine. This caused this vaccine to be FDA approved for metastatic castration-resistant prostate cancer patients.
|
|
|
|
|
Oncologist View - Local Treatment of Metastatic Prostate Cancer
Michael Zelefsky, MD, gave a talk about the oncologist’s view on local treatment of metastatic prostate cancer (MPC). The hypothesis that local therapy (LT) could prolong survival in MPC is based on several points.
|
|
|
|
|
Should the Primary Be Treated in Patients with Metastatic Disease?
Derya Tilki, MD gave a talk on whether local treatment should be given to M1 prostate cancer (PC). According to Dr. Tilki, treatment of the primary tumor in patients with metastatic PC is not ready for prime time.
|
|
|
|
|
|
|
|
|
|
|
|
